Kydaliv-Forte Infusion contains L-Ornithine L-Aspartate 5gm, an amino acid compound utilized primarily in the management of hepatic encephalopathy and related liver disorders. This formulation acts by enhancing the detoxification of ammonia through the urea cycle, thereby reducing elevated blood ammonia levels commonly observed in patients with liver cirrhosis and acute liver failure. The infusion is indicated for use in both acute and chronic hepatic encephalopathy to improve neurological symptoms and prevent progression of encephalopathy. Administered intravenously, Kydaliv-Forte facilitates rapid systemic absorption and prompt therapeutic effects. It is essential to monitor liver function tests and ammonia levels during treatment to assess efficacy and adjust dosing accordingly. The infusion should be used under strict medical supervision, especially in patients with severe hepatic impairment or concomitant renal dysfunction. Adverse effects are generally mild but may include local injection site reactions, gastrointestinal disturbances, or allergic responses. Kydaliv-Forte Infusion is contraindicated in patients with known hypersensitivity to L-Ornithine L-Aspartate or any excipients. Proper hydration and supportive care are recommended to optimize clinical outcomes. This product should be stored according to manufacturer guidelines and used within the specified shelf life to ensure potency and safety.